Synthesis, Characterization, Cytotoxicity Study and Docking Studies of New Fusedpyrazoline Derivatives derived from Bis-Chalcones against Breast Cancer cells

Abstract

Breast cancer is one of the prevalent diseases that kill millions of women worldwide. The development of resistance and side effects of chemotherapy drugs is a common obstacle in the treatment of breast cancer. Recently, the focus of drug discovery has increased toward a valuable structure known as chalcones due to their extensive bioactivity in cancer treatment. In this study, 6 chalcones and 4 fused-pyrazoline derivatives have been synthesized (1-6) using the Claisen-Schmidt condensation technique for cyclopentanone and cyclohexanone with different aromatic aldehydes at room temperature. Chalcones 2-3 and 5-6 were used in cyclo-condensation reaction with thiosemicarbazide to form new fused pyrazoline derivatives. All the synthesized chalcones and fused pyrazoline were characterized using ATR-FTIR, H-NMR and 13C-NMR (1D ). The cytotoxic activity of these new chalcone compounds was investigated against breast cancer cell lines (MCF-7) and normal breast cell lines (MCF-10A). The results showed that compounds 1 and 10 exhibited significant antiproliferative effects against MCF-7 with IC50 values of 8 μM and 8.5 μM when exposed for 48 hours compared with the reference anticancer drug, tamoxifen. Molecular docking analysis showed that compounds 1 and 10 entered the pocket of ERα and interaction with the amino acids in high affinity of binding as tamoxifen.